A Phase 4 interventional study of Early-Dexamethasone and Late dexamethazone in Covid19 and Anosmia, sponsored by ClinAmygate. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-06.
Sponsored by ClinAmygate · Phase 4, Interventional, and Treatment
Time to recover of Anosmia and / or ageusia and early corticosteroid use
In a study of dexamethasone kinetics in two groups of 15 patients with community-acquired pneumonia, one group was treated with dexamethasone 6 mg/day by mouth and the other with 4 mg/day intravenously. The apparent volume of distribution was 1 L/kg in both groups, but the half-life after oral administration was approximately 7 hours, and after intravenous administration 9 hours. The bioavailability of oral dexamethasone was 81% (95% CI = 54-121%). However, the biological half-life of dexamethasone is much longer, of the order of 36-54 h compared with 18-36 h for prednisolone.
Time to recover of Anosmia and / or ageusia and early corticosteroid use
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's planned enrollment of 300 is above the median of 102 across 4,364 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ClinAmygate is the lead sponsor of 18 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
early use of dexamethasone as early as the laboratory confirmation of inflammation.
Drug: Early-Dexamethasone
Dexamethasone is to be used lately upon the deterioration of cases
Drug: Late dexamethazone
early use of dexamethasone as early as laboratory evidence of high inflammatory markers
Also known as: Dexamethasone
Use of dexamethasone on deterioration of the cases with increased severity
Also known as: Dexamethasone
Time to recovery
Time to recovery from anosmia and / or agusia
Time frame: one to 6 weeks
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
ClinAmygate